Cardiometabolic Disease

Trials of SGLT2 inhibitors and GLP-1 receptor agonists, typically treatments for type 2 diabetes, have demonstrated potential CV and kidney benefits , according to a scientific statement from the American Heart Association.

Cumulative years of LDL exposure were significantly associated with risk for CVD events, according to findings published in the Journal of the American College of Cardiology.

Sleep-wake circadian rhythm is an important mechanism to maintain biological timekeeping, and disruptions from light exposure, dietary challenges and timing of food intake can have cardiometabolic consequences, according to a speaker.

Although a vegetarian diet may improve cardiometabolic health, researchers reported that obese individuals may need to do more than cut meat from their diets.

Obesity and elevated BMI are “the common soil” that grow adverse outcomes related to COVID-19, and clinicians must work with patients to appropriately control risk factors for severe disease, according to a speaker.

Organizers behind this year’s Heart in Diabetes conference are preparing to launch a free, all-virtual platform of sessions spanning all aspects of cardiometabolic health, along with a new emphasis on the impact of the COVID-19 pandemic.

The term “metabolic syndrome” has been used since the mid-1990s to describe a constellation of risk factors that predispose adults to develop diabetes, CVD or both.

Disparities in cardiometabolic mortality worsened between 1999 and 2017 between rural and urban Americans and within all race and sex groups for heart disease and diabetes, researchers found.

Recruitment for a global phase 3 trial is now underway to assess the potential of the SGLT2 inhibitor dapagliflozin as a treatment to reduce COVID-19 progression, complications and death among adults with cardiovascular, metabolic or renal risk factors, according to a press release from AstraZeneca and St. Luke’s Mid America Heart Institute.

Adults with obesity and unfavorable lifestyle factors are more likely to develop type 2 diabetes during 15 years of follow-up than those without excess weight and favorable lifestyle factors, regardless of their genetic predisposition for the disease, according to findings published in Diabetologia.